Stroke rehabilitation in adults

living. However, Dysport and Xeomin were only cost effective if certain doses were given and if: • the injections were spread across multiple points in the affected limbs and • the treatment was only given every 3 months and • treatment was based on the person's needs and discontinued if ineffective. The cost effectiveness of Botox in upper limb was not evaluated in the health economic analysis carried out for this update because there was a lack of clinical evidence relating to Modified Ashworth Scale responder outcomes. The published economic evidence regarding the use of Botox in the upper limb was also limited. Therefore, the committee agreed there was not enough evidence to support its use for this indication. Other preparations of botulinum toxin A are licensed for focal spasticity, including those that are referred to in SIGN's 2023 edition of the National clinical guideline for stroke for the UK and Ireland. If these preparations are already being used and are proving effective, then treatment with these can continue. There was no cost effectiveness evidence and insufficient clinical evidence to recommend botulinum toxin A for spasticity of the lower limb. Only 1 published health economic analysis included a lower limb
